SciSparc: Subsidiary NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette Syndrome

Phase 2SCI-110Positive

AI Analysis

Summary

SciSparc's subsidiary NeuroThera Labs initiated a Phase IIb clinical trial at Yale Child Study Center to evaluate SCI-110, a cannabinoid-based drug candidate, for the treatment of Tourette Syndrome in adults.

Clinical Trial Data

Phase

Phase IIb

Importance:5/10

Sentiment:

0.60

clinical trial initiationPhase IIbTourette SyndromecannabinoidCNS disorderssubsidiary announcement

Related Companies

$SPRC $NTLX

Read the original article

Published by GlobeNewswire Clinical Studies on August 5, 2026 12:22 PM

Read Original